March 9, 2020

FierceMedTech Names Thrive Earlier Detection as one of its “Fierce 15” Companies of 2019

 

Cambridge, Mass. — March 9, 2020 — Thrive Earlier Detection today announced that it has been named by FierceMedTech as one of 2019’s class of Fierce 15, designating it as one of the most promising private medtech companies in the industry.

 

Thrive launched in May 2019 with a mission to incorporate earlier cancer detection into routine medical care. Thrive is advancing CancerSEEK, a liquid biopsy test designed to detect multiple types of cancer at earlier stages of disease. CancerSEEK is currently being evaluated in DETECT-A, a prospective, interventional study of 10,000 healthy individuals conducted by Johns Hopkins University and Geisinger Health, to better understand safety and the implementation of its findings into patient care. Data from DETECT-A is expected to be announced this year.

 

“It is a tremendous honor to be among FierceMedTech’s elite ‘Fierce 15’ class of 2019,” stated David J. Daly, chief executive officer of Thrive.  “Thrive launched less than a year ago with a bold vision: a future where routine preventative care includes a blood test to detect multiple cancers earlier. We know that if cancer is caught early enough, it can often be cured, and we believe CancerSEEK has the potential to significantly change the course of cancer care for patients and their families.”

 

The Fierce 15 celebrates the spirit of being “fierce”—championing innovation and creativity, even in the face of intense competition. This is FierceMedTech’s 8th annual Fierce 15 selection. This year’s full list can be viewed at: https://www.fiercebiotech.com/special-report/fiercemedtech-s-2019-fierce-15

 

“One of the true joys of covering this field is being able to talk with the people driving the next great medical advancements—technologies that may not just change a patient or parent’s life, but also the day-to-day work of clinicians, surgeons, researchers and developers themselves,” said Conor Hale, associate editor of FierceMedTech. “Potential breakthroughs such as these can ripple into new therapies, procedures and interventions, and ultimately more ways to heal more people.”

 

An internationally recognized daily report reaching a network of over 90,000 medtech industry professionals, FierceMedTech provides subscribers with an authoritative analysis of the day’s top stories. Every year FierceMedTech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and competitive market position.

 

About FierceMedTech

FierceMedTech keeps biopharma executives, device developers, engineers, and researchers updated on the must-know news, trends and developments in medical technology. More than 90,000 top industry professionals rely on FierceMedTech for an insider briefing on the day’s top stories.

 

About Questex

Questex helps people live better and longer. Questex brings people together in the markets that help people live better: travel, hospitality and wellness; the industries that help people live longer: life science and healthcare; and the technologies that enable and fuel these new experiences. We live in the experience economy—connecting our ecosystem through live events, surrounded by data insights and digital communities. We deliver experience and real results. It happens here.

Press Contact

Katie Engleman
1AB

Thrive Earlier Detection Corp. is a healthcare company focused on incorporating earlier cancer detection into routine medical care to extend and save lives. Thrive is developing CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of disease that will serve as the core of its integrated cancer information offering. CancerSEEK is designed to be administered to healthy adults during routine medical care, such as a yearly checkup, alongside existing cancer screening tools. The company was launched in 2019 by Third Rock Ventures, with funding from additional investors Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group, Exact Sciences, and others. For more information, please visit www.thrivedetect.com.

Are you qualified?

Let's do this.